Phase II Study of Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Doxorubicin (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 16 Jun 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
- 16 Jun 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
- 17 Jun 2016 Status changed from recruiting to active, no longer recruiting.